Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 9/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.34 |
| ▸ | BRD7 | Q9NPI1 | 3/20 | 0.34 |
| ▸ | BRD2 | P25440 | 2/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15068063 | 0.80 | AURKA (0.33) | BRD4BRD9 | |
| SCHEMBL22990247 | 0.80 | MAP2K1 (0.35) | BRD4MAP2K1 | |
| SCHEMBL20704658 | 0.80 | BRD4 (0.33) | BRD4 | |
| SCHEMBL31180641 | 0.80 | MAP2K1 (0.33) | BRD4MAP2K1 | |
| SCHEMBL20704443 | 0.77 | BRD4 (0.33) | BRD4BRD9BRD7BRD2 | |
| SCHEMBL3450311 | 0.77 | GPR35 (0.37) | BRD4BRD9MAP2K1 | |
| SCHEMBL20709909 | 0.76 | MAPT (0.41) | — | |
| SCHEMBL23201571 | 0.75 | BRD4 (0.41) | BRD4BRD9BRD7BRD2 | |
| SCHEMBL9279323 | 0.74 | BRD4 (0.37) | BRD4BRD9BRD7BRD2 | |
| SCHEMBL15067937 | 0.74 | GRIN2D (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117229202-B | Preparation method of intermediate of BRD9 targeted degradation compound | 苏州美诺医药科技有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-117229202-A | Preparation method of intermediate of BRD9 targeted degradation compound | 苏州美诺医药科技有限公司 | 2023-12-15 | — | — | CN | claimed |
| US-12624035-B2 | Compounds for targeted protein degradation | AMPHISTA THERAPEUTICS LIMITED (GB) | 2026-05-12 | — | — | US | disclosed |
| EP-4720040-A1 | SULFONAMIDE COMPOUNDS BENEFICIAL IN NEUROPROTECTIVE TREATMENT | Lario Therapeutics Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
| US-20260070904-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2026-03-12 | — | — | US | disclosed |
| US-12384760-B2 | Substituted carbazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4134364-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250195484-A1 | CEREBLON LIGANDS AND USES THEREOF | UNIV MICHIGAN (US) | 2025-06-19 | — | — | US | disclosed |
| CN-119823124-A | Compounds for targeted degradation of BRD9 | C4医药公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-07-02 | — | — | US | disclosed |
| US-9034900-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034900-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034900-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-05-19 | — | — | US | disclosed |
| WO-2015058160-A1 | BROMODOMAIN INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015058160-A1 | BROMODOMAIN INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195484-A1 | CEREBLON LIGANDS AND USES THEREOF | CRBN, CDR2, CHLSN | BRD4 1042/4885BRD9 820/4885BRD7 370/4885 |
| US-20260070904-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BRD9, BRWD1, BRD1 | BRD4 14/4885BRD9 1/4885BRD7 9/4885 |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885BRD9 19/4885BRD7 14/4885 |
| US-12624035-B2 | Compounds for targeted protein degradation | BRD9, BRD1, BRD3 | BRD4 9/4885BRD9 1/4885BRD7 7/4885 |
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | BRD4 161/4885BRD9 3/4885BRD7 18/4885 |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885BRD9 19/4885BRD7 14/4885 |
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | BRD4 30/4885BRD9 1/4885BRD7 8/4885 |
| US-12384760-B2 | Substituted carbazole compounds | TLR7, TLR3, TLR1 | BRD4 169/4885BRD9 456/4885BRD7 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.